Will these Stocks Surge? Raptor Pharmaceutical Corp. (RPTP), Sangamo Biosciences, Inc. (SGMO)

0
107

Raptor Pharmaceutical Corp. (NASDAQ:RPTP

Stock’s Trading Stats:

Raptor Pharmaceutical Corp. (NASDAQ:RPTP surged 1.55% yesterday and closed at $4.58. The company’s market capitalization is at $382.78Million with an average trading volume of 1.16Million. The total number of Outstanding Shares Held by the company are 85.24 Million.

Recent Press Release:

Raptor Pharmaceutical Corp (RPTP) on March 21, 2016 declared that Health Canada has accepted for review its New Drug Submission (NDS) for PROCYSBI delayed-release capsules for the treatment of nephropathic cystinosis (NC), with Priority Review status. Priority Review provides for a shortened review process of 180 days contrast to a standard 300 days. Raptor estimates, based on information offered by physicians, that there are about 100 individuals affected by nephropathic cystinosis in Canada. PROCYSBI, a cystine depleting agent, is approved in the U.S. for the treatment of NC in adults and children ages two years and older and in all patients with NC in Europe.

About PROCYSBI (cysteamine bitartrate) delayed-release capsules

PROCYSBI is a cystine depleting agent that is approved in the U.S. for the treatment of nephropathic cystinosis in adults and children ages two years and older. It is contraindicated in patients with a hypersensitivity to penicillamine. The most commonly stated side effects are vomiting, abdominal pain/discomfort, headaches, nausea, diarrhea, anorexia/reduced appetite, breath odor, fatigue, dizziness, skin odor and rash.

Sangamo Biosciences, Inc. (NASDAQ:SGMO)

Stock’s Trading Stats:

Sangamo Biosciences, Inc. (NASDAQ:SGMO) closed at $6.31 yesterday by showing a increase of 1.61%. The total number of outstanding shares held by the company are 70.37Million with the total market capitalization of $455.77 Million. The number of shares traded on the last trading session are 1.11 Million.

Recent Press Release:

Sangamo Biosciences, Inc. (SGMO) a clinical stage biopharmaceutical company, focused on the research, development, and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation. Its proprietary zinc finger DNA-binding protein (ZFP) technology facilitates specific genome modification and gene regulation. The ZFPs can also be linked to a cleavage domain of a restriction endonuclease to create zinc finger nucleases (ZFNs), proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its lead ZFP Therapeutic candidate include SB-728-T, a ZFN-mediated autologous cell product for the treatment of human immunodeficiency virus and attained immunodeficiency syndrome (HIV/AIDS) is in Phase II and Phase I/II clinical trials.